Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Consort Medical

BATS-CHIXE:CSRTl
Snowflake Description

Reasonable growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CSRTl
BATS-CHIXE
£496M
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices in Europe, the United States, the United Kingdom, and internationally. The last earnings update was 76 days ago. More info.


Add to Portfolio Compare Print
  • Consort Medical has significant price volatility in the past 3 months.
CSRTl Share Price and Events
7 Day Returns
0.7%
BATS-CHIXE:CSRTl
-1.5%
GB Medical Equipment
-0.2%
GB Market
1 Year Returns
11.9%
BATS-CHIXE:CSRTl
30.4%
GB Medical Equipment
6.1%
GB Market
CSRTl Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Consort Medical (CSRTl) 0.7% -1.2% -3.3% 11.9% -0.3% -
GB Medical Equipment -1.5% -2.7% 9.3% 30.4% 32.9% 52.9%
GB Market -0.2% -2.7% 3.9% 6.1% 2.6% 3.7%
1 Year Return vs Industry and Market
  • CSRTl underperformed the Medical Equipment industry which returned 30.4% over the past year.
  • CSRTl outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned 6.1% over the past year.
Price Volatility
CSRTl
Industry
5yr Volatility vs Market

CSRTl Value

 Is Consort Medical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Consort Medical to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Consort Medical.

BATS-CHIXE:CSRTl Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.6%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:CSRTl
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 6.1%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.82
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.821 (1 + (1- 19%) (25.61%))
0.994
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.99
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (0.994 * 6.07%)
6.57%

Discounted Cash Flow Calculation for BATS-CHIXE:CSRTl using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Consort Medical is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:CSRTl DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (GBP, Millions) Source Present Value
Discounted (@ 6.57%)
2020 9.20 Analyst x1 8.63
2021 27.75 Analyst x2 24.44
2022 31.80 Analyst x1 26.28
2023 34.64 Est @ 8.92% 26.86
2024 36.86 Est @ 6.41% 26.82
2025 38.57 Est @ 4.64% 26.33
2026 39.88 Est @ 3.41% 25.55
2027 40.90 Est @ 2.55% 24.59
2028 41.69 Est @ 1.94% 23.52
2029 42.32 Est @ 1.52% 22.41
Present value of next 10 years cash flows £235.00
BATS-CHIXE:CSRTl DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= £42.32 × (1 + 0.53%) ÷ (6.57% – 0.53%)
£704.97
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= £704.97 ÷ (1 + 6.57%)10
£373.25
BATS-CHIXE:CSRTl Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= £235.00 + £373.25
£608.25
Equity Value per Share
(GBP)
= Total value / Shares Outstanding
= £608.25 / 49.10
£12.39
BATS-CHIXE:CSRTl Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:CSRTl represents 1.00995x of LSE:CSRT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.00995x
Value per Share
(Listing Adjusted, GBP)
= Value per Share (GBP) x Listing Adjustment Factor
= £ 12.39 x 1.00995
£12.51
Value per share (GBP) From above. £12.51
Current discount Discount to share price of £10.15
= -1 x (£10.15 - £12.51) / £12.51
18.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Consort Medical is available for.
Intrinsic value
19%
Share price is £10.15 vs Future cash flow value of £12.51
Current Discount Checks
For Consort Medical to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Consort Medical's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Consort Medical's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Consort Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Consort Medical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:CSRTl PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-10-31) in GBP £0.08
LSE:CSRT Share Price ** LSE (2020-02-14) in GBP £10.05
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PE Ratio Median Figure of 11 Publicly-Listed Medical Equipment Companies 33.63x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 755 Publicly-Listed Companies 18.53x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Consort Medical.

BATS-CHIXE:CSRTl PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= LSE:CSRT Share Price ÷ EPS (both in GBP)

= 10.05 ÷ 0.08

126.48x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Consort Medical is overvalued based on earnings compared to the GB Medical Equipment industry average.
  • Consort Medical is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Consort Medical's expected growth come at a high price?
Raw Data
BATS-CHIXE:CSRTl PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 126.48x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
39.3%per year
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PEG Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 2.53x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 549 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

BATS-CHIXE:CSRTl PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 126.48x ÷ 39.3%

3.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Consort Medical is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Consort Medical's assets?
Raw Data
BATS-CHIXE:CSRTl PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-10-31) in GBP £4.66
LSE:CSRT Share Price * LSE (2020-02-14) in GBP £10.05
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PB Ratio Median Figure of 19 Publicly-Listed Medical Equipment Companies 3.25x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,319 Publicly-Listed Companies 1.62x
BATS-CHIXE:CSRTl PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= LSE:CSRT Share Price ÷ Book Value per Share (both in GBP)

= 10.05 ÷ 4.66

2.16x

* Primary Listing of Consort Medical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Consort Medical is good value based on assets compared to the GB Medical Equipment industry average.
X
Value checks
We assess Consort Medical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Consort Medical has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CSRTl Future Performance

 How is Consort Medical expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
39.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Consort Medical expected to grow at an attractive rate?
  • Consort Medical's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Consort Medical's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
  • Consort Medical's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:CSRTl Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:CSRTl Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 39.3%
BATS-CHIXE:CSRTl Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 3.6%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 11.4%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.3%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 12.2%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 3.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:CSRTl Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:CSRTl Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-04-30 342 1
2023-04-30 341 54 34 2
2022-04-30 332 52 27 6
2021-04-30 322 48 23 7
2020-04-30 302 34 12 4
2020-02-17
BATS-CHIXE:CSRTl Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2019-10-31 299 15 4
2019-07-31 302 25 7
2019-04-30 305 35 11
2019-01-31 308 36 14
2018-10-31 310 37 17
2018-07-31 311 34 16
2018-04-30 311 32 16
2018-01-31 307 40 18
2017-10-31 303 47 20
2017-07-31 298 44 21
2017-04-30 294 41 23
2017-01-31 290 35 21

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Consort Medical's earnings are expected to grow significantly at over 20% yearly.
  • Consort Medical's revenue is expected to grow by 3.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:CSRTl Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Consort Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:CSRTl Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-04-30
2023-04-30 0.69 0.69 0.69 1.00
2022-04-30 0.56 0.64 0.47 4.00
2021-04-30 0.48 0.55 0.38 4.00
2020-04-30 0.25 0.35 0.19 4.00
2020-02-17
BATS-CHIXE:CSRTl Past Financials Data
Date (Data in GBP Millions) EPS *
2019-10-31 0.08
2019-07-31 0.15
2019-04-30 0.21
2019-01-31 0.28
2018-10-31 0.34
2018-07-31 0.34
2018-04-30 0.33
2018-01-31 0.37
2017-10-31 0.40
2017-07-31 0.43
2017-04-30 0.46
2017-01-31 0.43

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Consort Medical is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Consort Medical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Consort Medical has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CSRTl Past Performance

  How has Consort Medical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Consort Medical's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Consort Medical's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
  • Consort Medical's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Consort Medical's 1-year earnings growth is negative, it can't be compared to the GB Medical Equipment industry average.
Earnings and Revenue History
Consort Medical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Consort Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:CSRTl Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-10-31 298.60 3.90 0.30
2019-07-31 301.85 7.20 0.30
2019-04-30 305.10 10.50 0.30
2019-01-31 307.50 13.65 0.50
2018-10-31 309.90 16.80 0.70
2018-07-31 310.50 16.45 0.90
2018-04-30 311.10 16.10 1.10
2018-01-31 306.95 17.95 1.05
2017-10-31 302.80 19.80 1.00
2017-07-31 298.40 21.20 0.90
2017-04-30 294.00 22.60 0.80
2017-01-31 290.13 21.23 82.13
2016-10-31 286.25 19.86 163.46
2016-07-31 281.58 17.93 163.43
2016-04-30 276.90 16.00 163.40
2016-01-31 271.84 10.48 133.94
2015-10-31 266.78 4.96 104.48
2015-07-31 225.80 5.61 104.33
2015-04-30 184.83 6.26 104.18
2015-01-31 143.62 9.88 76.59
2014-10-31 102.42 13.50 49.01
2014-07-31 101.22 13.57 49.11
2014-04-30 100.01 13.65 49.21
2014-01-31 99.08 13.30 46.03
2013-10-31 98.15 12.94 42.85
2013-07-31 96.60 11.92 42.76
2013-04-30 95.04 10.89 42.67

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Consort Medical has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Consort Medical used its assets less efficiently than the GB Medical Equipment industry average last year based on Return on Assets.
  • Consort Medical's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Consort Medical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Consort Medical has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CSRTl Health

 How is Consort Medical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Consort Medical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Consort Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Consort Medical's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Consort Medical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Consort Medical Company Filings, last reported 3 months ago.

BATS-CHIXE:CSRTl Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2019-10-31 228.50 127.00 14.80
2019-07-31 228.50 127.00 14.80
2019-04-30 238.20 110.90 13.50
2019-01-31 238.20 110.90 13.50
2018-10-31 246.90 119.40 24.10
2018-07-31 246.90 119.40 24.10
2018-04-30 246.30 116.90 21.40
2018-01-31 246.30 116.90 21.40
2017-10-31 232.10 125.00 27.90
2017-07-31 232.10 125.00 27.90
2017-04-30 212.10 114.80 22.20
2017-01-31 212.10 114.80 22.20
2016-10-31 210.97 122.98 16.22
2016-07-31 210.97 122.98 16.22
2016-04-30 209.10 113.20 16.20
2016-01-31 209.10 113.20 16.20
2015-10-31 199.46 106.87 11.58
2015-07-31 199.46 106.87 11.58
2015-04-30 200.49 144.41 45.20
2015-01-31 200.49 144.41 45.20
2014-10-31 116.35 0.00 30.00
2014-07-31 116.35 0.00 30.00
2014-04-30 118.52 0.00 25.84
2014-01-31 118.52 0.00 25.84
2013-10-31 107.45 0.00 33.63
2013-07-31 107.45 0.00 33.63
2013-04-30 103.76 0.00 36.97
  • Consort Medical's level of debt (55.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (1.3% vs 55.6% today).
  • Debt is not well covered by operating cash flow (11.8%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 8.8x coverage).
X
Financial health checks
We assess Consort Medical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Consort Medical has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CSRTl Dividends

 What is Consort Medical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Consort Medical dividends. Estimated to be 2.36% next year.
If you bought £2,000 of Consort Medical shares you are expected to receive £0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Consort Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Consort Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:CSRTl Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.6%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 679 Stocks 4.4%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.1%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 1.8%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 5.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:CSRTl Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2024-04-30 0.28 1.00
2023-04-30 0.26 2.00
2022-04-30 0.24 6.00
2021-04-30 0.23 7.00
2020-04-30 0.22 2.00
2020-02-17
BATS-CHIXE:CSRTl Past Annualized Dividends Data
Date (Data in £) Dividend per share (annual) Avg. Yield (%)
2019-12-03 0.000 0.000
2019-09-11 0.214 2.732
2018-12-04 0.212 2.510
2018-07-30 0.210 1.865
2018-06-14 0.210 1.803
2017-06-29 0.203 1.800
2017-06-15 0.203 1.921
2016-07-28 0.193 1.849
2016-06-16 0.193 1.871
2015-07-29 0.181 1.844
2015-06-16 0.181 1.989
2014-06-18 0.207 2.379
2013-06-13 0.197 2.208
2012-06-14 0.191 2.578
2012-06-13 0.191 3.175
2011-07-28 0.191 3.417
2011-06-16 0.191 3.600
2010-07-27 0.191 3.912
2010-06-17 0.191 5.035
2009-10-12 0.191 5.126
2009-06-24 0.191 4.932

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Consort Medical has not reported any payouts.
  • Unable to verify if Consort Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Consort Medical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Consort Medical has not reported any payouts.
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (3x coverage).
X
Income/ dividend checks
We assess Consort Medical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Consort Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Consort Medical has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CSRTl Management

 What is the CEO of Consort Medical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mark Quick
AGE 53
TENURE AS CEO 0 years
CEO Bio

Mr. Mark Quick has been Chief Executive Officer at Consort Medical plc since February 2020. He serves as an Executive Vice President of Corporate Development at Recipharm AB and Recipharm AB (publ). Mr. Quick serves as the Head of Business Development at Recipharm Ltd. He served as Head of Business Development at Celltech Manufacturing Services from 2000 to 2006. He received a B.Sc. (Hons) in Industrial Studies from Nottingham Trent University in 1988 and MBA from Open University in 2005.

CEO Compensation
  • Insufficient data for Mark to compare compensation growth.
  • Insufficient data for Mark to establish whether their remuneration is reasonable compared to companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure of the Consort Medical management team in years:

2.1
Average Tenure
  • The tenure for the Consort Medical management team is about average.
Management Team

Paul Hayes

TITLE
CFO & Executive Director
COMPENSATION
£635K
AGE
52
TENURE
2.8 yrs

Mark Quick

TITLE
Chief Executive Officer
AGE
53

Kevin Cunningham

TITLE
Vice President of Operations
TENURE
1.1 yrs

Andrew Jackson

TITLE
Group General Counsel & Company Secretary
TENURE
1.5 yrs

Lisa King

TITLE
Director of Human Resources
TENURE
11.5 yrs

Colin Leeder

TITLE
Group Financial Controller

Keyvan Djamarani

TITLE
Business President of Bespak Drug Delivery Devices
TENURE
2.1 yrs
Board of Directors Tenure

Average tenure and age of the Consort Medical board of directors in years:

6.6
Average Tenure
54
Average Age
  • The tenure for the Consort Medical board of directors is about average.
Board of Directors

Thomas Eldered

TITLE
Chairman
AGE
59

Paul Hayes

TITLE
CFO & Executive Director
COMPENSATION
£635K
AGE
52
TENURE
2.8 yrs

William Jenkins

TITLE
Senior Independent Director
COMPENSATION
£66K
AGE
72
TENURE
8.4 yrs

Steve Crummett

TITLE
Non-Executive Director
COMPENSATION
£50K
AGE
54
TENURE
7.7 yrs

Ian Nicholson

TITLE
Non-Executive Director
COMPENSATION
£47K
AGE
59
TENURE
7.7 yrs

Drew Hosty

TITLE
Non Executive Director
COMPENSATION
£45K
AGE
54
TENURE
5.6 yrs

Maria Ginman-Horrell

TITLE
Non-Executive Director
COMPENSATION
£42K
AGE
53
TENURE
5 yrs
Who owns this company?
Recent Insider Trading
  • Consort Medical individual insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (£) Value (£)
04. Feb 20 Buy Groupe BPCE Company 31. Jan 20 31. Jan 20 590,000 £10.05 £5,929,500
20. Dec 19 Sell Barclays PLC Private Banking & Investment Banking Investment Company 19. Dec 19 19. Dec 19 -3,711 £10.35 £-38,155
20. Dec 19 Buy Barclays PLC Private Banking & Investment Banking Investment Company 19. Dec 19 19. Dec 19 2,460 £10.37 £25,369
20. Nov 19 Sell Revera Asset Management Limited Company 18. Nov 19 18. Nov 19 -300,000 £10.41 £-3,123,750
13. Jan 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 10. Jan 20 10. Jan 20 -2,771 £10.30 £-28,453
13. Jan 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 10. Jan 20 10. Jan 20 1,134 £10.32 £11,700
30. Dec 19 Sell Barclays PLC Private Banking & Investment Banking Investment Company 27. Dec 19 27. Dec 19 -1,218 £10.25 £-12,484
30. Dec 19 Buy Barclays PLC Private Banking & Investment Banking Investment Company 27. Dec 19 27. Dec 19 222 £10.35 £2,294
06. Feb 20 Sell Paul Hayes Individual 05. Feb 20 05. Feb 20 -467 £10.10 £-4,717
06. Feb 20 Sell Keyvan Djamarani Individual 05. Feb 20 05. Feb 20 -1,971 £10.10 £-19,907
06. Feb 20 Sell Jonathan Glenn Individual 05. Feb 20 05. Feb 20 -9,065 £10.10 £-91,556
05. Feb 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 04. Feb 20 04. Feb 20 -8,388 £10.10 £-84,368
05. Feb 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 04. Feb 20 04. Feb 20 321,626 £10.10 £3,248,384
04. Feb 20 Sell Legal & General Investment Management Limited Company 03. Feb 20 03. Feb 20 -200,000 £10.03 £-2,005,000
04. Feb 20 Sell Liontrust Investment Partners LLP Company 23. Jan 20 23. Jan 20 -579,000 £10.08 £-5,833,425
04. Feb 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 03. Feb 20 03. Feb 20 -9,487 £10.10 £-95,124
04. Feb 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 03. Feb 20 03. Feb 20 110,211 £10.10 £1,105,301
03. Feb 20 Sell Montanaro Investment Managers Ltd. Company 31. Jan 20 31. Jan 20 -49,000 £10.03 £-491,225
03. Feb 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 29. Jan 20 29. Jan 20 -23,820 £10.05 £-238,563
03. Feb 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 29. Jan 20 29. Jan 20 526,169 £10.05 £5,274,595
03. Feb 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 31. Jan 20 31. Jan 20 -422 £10.05 £-4,241
03. Feb 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 31. Jan 20 31. Jan 20 149 £10.05 £1,497
31. Jan 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 30. Jan 20 30. Jan 20 -489 £10.01 £-4,891
31. Jan 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 30. Jan 20 30. Jan 20 783 £10.05 £7,862
30. Jan 20 Buy Water Island Capital, LLC Company 29. Jan 20 29. Jan 20 2,177 £10.00 £21,770
30. Jan 20 Sell Janus Henderson Group plc Company 29. Jan 20 29. Jan 20 -926,872 £10.05 £-9,315,063
29. Jan 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 28. Jan 20 28. Jan 20 -1,863 £10.24 £-19,011
29. Jan 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 28. Jan 20 28. Jan 20 3,376 £10.20 £34,372
29. Jan 20 Sell Royal London Asset Management Limited Company 28. Jan 20 28. Jan 20 -542,500 £10.18 £-5,479,784
28. Jan 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 27. Jan 20 27. Jan 20 -1,075 £10.15 £-10,889
28. Jan 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 27. Jan 20 27. Jan 20 320,088 £10.15 £3,235,133
28. Jan 20 Sell Royal London Asset Management Limited Company 27. Jan 20 27. Jan 20 -131,500 £10.10 £-1,328,150
28. Jan 20 Buy J O Hambro Capital Management Limited Company 27. Jan 20 27. Jan 20 2,071 £10.10 £20,917
27. Jan 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 24. Jan 20 24. Jan 20 -13,027 £10.30 £-131,678
27. Jan 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 24. Jan 20 24. Jan 20 689,065 £10.32 £6,966,155
27. Jan 20 Sell Highclere International Investors LLP Company 24. Jan 20 24. Jan 20 -865,492 £10.10 £-8,741,469
24. Jan 20 Buy Recipharm AB (publ) Company 22. Jan 20 22. Jan 20 5,000,000 £10.10 £50,481,501
24. Jan 20 Sell Royal London Asset Management Limited Company 23. Jan 20 23. Jan 20 -172,363 £10.10 £-1,735,769
24. Jan 20 Buy Kabouter Management L.L.C. Company 23. Jan 20 23. Jan 20 1,245,186 £10.09 £12,563,927
23. Jan 20 Buy Water Island Capital, LLC Company 22. Jan 20 22. Jan 20 14,136 £10.07 £142,350
23. Jan 20 Sell J O Hambro Capital Management Limited Company 22. Jan 20 22. Jan 20 -700 £10.08 £-7,053
23. Jan 20 Buy J O Hambro Capital Management Limited Company 22. Jan 20 22. Jan 20 556,846 £10.08 £5,607,443
23. Jan 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 22. Jan 20 22. Jan 20 -1,332 £10.10 £-13,435
23. Jan 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 22. Jan 20 22. Jan 20 42,611 £10.10 £429,168
23. Jan 20 Sell Royal London Asset Management Limited Company 22. Jan 20 22. Jan 20 -3,657 £10.10 £-36,936
23. Jan 20 Sell Highclere International Investors LLP Company 22. Jan 20 22. Jan 20 -823,594 £10.06 £-8,281,567
23. Jan 20 Sell Kabouter Management L.L.C. Company 22. Jan 20 22. Jan 20 -786,426 £10.07 £-7,919,310
22. Jan 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 21. Jan 20 21. Jan 20 -55,159 £10.20 £-557,617
22. Jan 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 21. Jan 20 21. Jan 20 555,279 £10.20 £5,656,241
22. Jan 20 Sell Polar Capital Holdings plc Company 21. Jan 20 21. Jan 20 -249 £10.20 £-2,540
22. Jan 20 Sell J O Hambro Capital Management Limited Company 21. Jan 20 21. Jan 20 -3,700 £10.15 £-37,400
22. Jan 20 Buy J O Hambro Capital Management Limited Company 21. Jan 20 21. Jan 20 600 £10.15 £6,090
22. Jan 20 Sell Wellington Management Group LLP Company 21. Jan 20 21. Jan 20 -478,750 £10.20 £-4,883,250
22. Jan 20 Sell Wellington Management Group LLP Company 14. Jan 20 14. Jan 20 -90,974 £10.25 £-932,483
21. Jan 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 20. Jan 20 20. Jan 20 -629 £10.25 £-6,438
21. Jan 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 20. Jan 20 20. Jan 20 3,337 £10.30 £34,224
21. Jan 20 Sell Polar Capital Holdings plc Company 20. Jan 20 20. Jan 20 -197,957 £10.30 £-2,038,957
21. Jan 20 Sell Montanaro Investment Managers Ltd. Company 20. Jan 20 20. Jan 20 -800,000 £10.26 £-8,204,000
20. Jan 20 Sell Legal & General Investment Management Limited Company 17. Jan 20 17. Jan 20 -2,913 £10.25 £-29,858
20. Jan 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 17. Jan 20 17. Jan 20 -4,332 £10.28 £-44,413
20. Jan 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 17. Jan 20 17. Jan 20 608,699 £10.30 £6,242,995
20. Jan 20 Buy J O Hambro Capital Management Limited Company 17. Jan 20 17. Jan 20 300 £10.30 £3,090
20. Jan 20 Sell Polar Capital Holdings plc Company 17. Jan 20 17. Jan 20 -1,150,000 £10.25 £-11,787,500
17. Jan 20 Sell BlackRock, Inc. Company 16. Jan 20 16. Jan 20 -339 £10.30 £-3,483
17. Jan 20 Buy BlackRock, Inc. Company 16. Jan 20 16. Jan 20 1,396 £10.30 £14,379
15. Jan 20 Sell BlackRock, Inc. Company 14. Jan 20 14. Jan 20 -3,832 £10.31 £-39,490
15. Jan 20 Sell Liontrust Investment Partners LLP Company 14. Jan 20 14. Jan 20 -155,256 £10.25 £-1,591,374
17. Jan 20 Sell Kabouter Management L.L.C. Company 16. Jan 20 16. Jan 20 -458,760 £10.25 £-4,702,290
17. Jan 20 Buy Aviva Investors Global Services Limited Company 16. Jan 20 16. Jan 20 388 £10.30 £3,996
17. Jan 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 16. Jan 20 16. Jan 20 -5,416 £10.30 £-55,777
17. Jan 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 16. Jan 20 16. Jan 20 6,728 £10.30 £69,283
17. Jan 20 Sell Polar Capital Holdings plc Company 16. Jan 20 16. Jan 20 -20,812 £10.30 £-214,364
16. Jan 20 Sell BlackRock, Inc. Company 15. Jan 20 15. Jan 20 -22,580 £10.33 £-232,476
16. Jan 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 15. Jan 20 15. Jan 20 -2,894 £10.35 £-29,803
16. Jan 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 15. Jan 20 15. Jan 20 1,311 £10.35 £13,525
16. Jan 20 Sell Polar Capital Holdings plc Company 15. Jan 20 15. Jan 20 -263,108 £10.30 £-2,710,012
15. Jan 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 14. Jan 20 14. Jan 20 -2,744 £10.35 £-28,314
15. Jan 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 14. Jan 20 14. Jan 20 221,319 £10.35 £2,270,157
15. Jan 20 Sell Columbia Management Investment Advisers, LLC Company 14. Jan 20 14. Jan 20 -1,000 £10.26 £-10,260
14. Jan 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 13. Jan 20 13. Jan 20 -6,828 £10.40 £-70,684
14. Jan 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 13. Jan 20 13. Jan 20 4,246 £10.40 £44,049
13. Jan 20 Buy Jonathan Glenn Individual 07. Jan 20 07. Jan 20 14 £10.30 £144
13. Jan 20 Buy Aviva Investors Global Services Limited Company 10. Jan 20 10. Jan 20 580 £10.25 £5,945
13. Jan 20 Buy Paul Hayes Individual 07. Jan 20 07. Jan 20 15 £10.30 £154
10. Jan 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 09. Jan 20 09. Jan 20 -2,964 £10.35 £-30,664
10. Jan 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 09. Jan 20 09. Jan 20 2,231 £10.35 £23,090
09. Jan 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 08. Jan 20 08. Jan 20 -659 £10.45 £-6,868
09. Jan 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 08. Jan 20 08. Jan 20 182 £10.45 £1,902
08. Jan 20 Sell AXA Investment Managers S.A. Company 07. Jan 20 07. Jan 20 -70,697 £10.30 £-728,179
08. Jan 20 Sell Altaone Capital LLP Company 07. Jan 20 07. Jan 20 -194,825 £10.31 £-2,008,646
08. Jan 20 Buy Aviva Investors Global Services Limited Company 07. Jan 20 07. Jan 20 282 £10.35 £2,919
08. Jan 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 07. Jan 20 07. Jan 20 -830 £10.35 £-8,577
08. Jan 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 07. Jan 20 07. Jan 20 15,981 £10.35 £164,620
08. Jan 20 Buy J O Hambro Capital Management Limited Company 08. Jan 20 08. Jan 20 221,578 £10.30 £2,282,248
07. Jan 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 06. Jan 20 06. Jan 20 -804 £10.30 £-8,270
07. Jan 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 06. Jan 20 06. Jan 20 100,314 £10.30 £1,028,944
07. Jan 20 Sell BlackRock, Inc. Company 06. Jan 20 06. Jan 20 -1,295,348 £10.28 £-13,287,327
07. Jan 20 Sell Altaone Capital LLP Company 06. Jan 20 06. Jan 20 -75,000 £10.25 £-768,750
06. Jan 20 Buy BlackRock, Inc. Company 03. Jan 20 03. Jan 20 1,432 £10.34 £14,810
06. Jan 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 03. Jan 20 03. Jan 20 -1,351 £10.35 £-13,966
06. Jan 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 03. Jan 20 03. Jan 20 792 £10.35 £8,196
06. Jan 20 Buy J O Hambro Capital Management Limited Company 03. Jan 20 03. Jan 20 8,600 £10.33 £88,866
03. Jan 20 Sell Wellington Management Group LLP Company 02. Jan 20 02. Jan 20 -13,538 £10.30 £-139,421
03. Jan 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 02. Jan 20 02. Jan 20 -1,835 £10.34 £-18,927
03. Jan 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 02. Jan 20 02. Jan 20 181 £10.30 £1,864
03. Jan 20 Buy J O Hambro Capital Management Limited Company 02. Jan 20 02. Jan 20 100 £10.35 £1,035
02. Jan 20 Sell Barclays PLC Private Banking & Investment Banking Investment Company 31. Dec 19 31. Dec 19 -482 £10.25 £-4,941
02. Jan 20 Buy Barclays PLC Private Banking & Investment Banking Investment Company 31. Dec 19 31. Dec 19 1,300 £10.25 £13,325
31. Dec 19 Sell Legal & General Investment Management Limited Company 30. Dec 19 30. Dec 19 -3,542 £10.30 £-36,483
27. Dec 19 Buy Barclays PLC Private Banking & Investment Banking Investment Company 24. Dec 19 24. Dec 19 261 £10.35 £2,698
05. Dec 19 Sell Wellington Management Group LLP Company 04. Dec 19 04. Dec 19 -25,000 £10.40 £-260,000
24. Dec 19 Sell Barclays PLC Private Banking & Investment Banking Investment Company 23. Dec 19 23. Dec 19 -682 £10.35 £-7,017
24. Dec 19 Buy Barclays PLC Private Banking & Investment Banking Investment Company 23. Dec 19 23. Dec 19 1,817 £10.35 £18,758
24. Dec 19 Sell Aviva Investors Global Services Limited Company 23. Dec 19 23. Dec 19 -195 £10.25 £-1,999
24. Dec 19 Sell Michael Schumann Individual 20. Dec 19 20. Dec 19 -5,535 £10.25 £-56,734
23. Dec 19 Sell Altaone Capital LLP Company 20. Dec 19 20. Dec 19 -72,425 £10.50 £-760,462
23. Dec 19 Sell Barclays PLC Private Banking & Investment Banking Investment Company 20. Dec 19 20. Dec 19 -5,412 £10.50 £-56,545
23. Dec 19 Buy Barclays PLC Private Banking & Investment Banking Investment Company 20. Dec 19 20. Dec 19 804 £10.50 £8,364
23. Dec 19 Buy BlackRock, Inc. Company 20. Dec 19 20. Dec 19 125,351 £10.49 £1,314,697
19. Dec 19 Sell AXA Investment Managers S.A. Company 18. Dec 19 18. Dec 19 -54,093 £10.25 £-554,453
20. Dec 19 Sell Columbia Management Investment Advisers, LLC Company 19. Dec 19 19. Dec 19 -1,342 £10.30 £-13,823
20. Dec 19 Sell BlackRock, Inc. Company 19. Dec 19 19. Dec 19 -39,512 £10.35 £-408,949
20. Dec 19 Buy BlackRock, Inc. Company 19. Dec 19 19. Dec 19 2,116 £10.35 £21,899
19. Dec 19 Sell J O Hambro Capital Management Limited Company 18. Dec 19 18. Dec 19 -200 £10.25 £-2,050
19. Dec 19 Buy BlackRock, Inc. Company 18. Dec 19 18. Dec 19 758 £10.27 £7,786
19. Dec 19 Sell Barclays PLC Private Banking & Investment Banking Investment Company 18. Dec 19 18. Dec 19 -1,432 £10.30 £-14,683
19. Dec 19 Buy Barclays PLC Private Banking & Investment Banking Investment Company 18. Dec 19 18. Dec 19 3,810 £10.30 £39,070
18. Dec 19 Sell AXA Investment Managers S.A. Company 17. Dec 19 17. Dec 19 -209,229 £10.30 £-2,155,059
17. Dec 19 Sell AXA Investment Managers S.A. Company 16. Dec 19 16. Dec 19 -29,467 £10.40 £-306,457
18. Dec 19 Sell Barclays PLC Private Banking & Investment Banking Investment Company 17. Dec 19 17. Dec 19 -13,134 £10.30 £-135,268
18. Dec 19 Buy Barclays PLC Private Banking & Investment Banking Investment Company 17. Dec 19 17. Dec 19 812 £10.35 £8,404
18. Dec 19 Sell Merian Global Investors (UK) Limited Company 17. Dec 19 17. Dec 19 -652,181 £10.30 £-6,717,464
17. Dec 19 Sell Wellington Management Group LLP Company 16. Dec 19 16. Dec 19 -3,368 £10.35 £-34,859
17. Dec 19 Sell Invesco Ltd. Company 16. Dec 19 16. Dec 19 -22,028 £10.40 £-229,091
17. Dec 19 Sell Barclays PLC Private Banking & Investment Banking Investment Company 16. Dec 19 16. Dec 19 -4,746 £10.40 £-49,141
17. Dec 19 Buy Barclays PLC Private Banking & Investment Banking Investment Company 16. Dec 19 16. Dec 19 4,388 £10.40 £45,467
17. Dec 19 Sell Legal & General Investment Management Limited Company 16. Dec 19 16. Dec 19 -200,000 £10.43 £-2,086,000
17. Dec 19 Buy Polar Capital Holdings plc Company 16. Dec 19 16. Dec 19 22,028 £10.40 £229,091
16. Dec 19 Sell Barclays PLC Private Banking & Investment Banking Investment Company 13. Dec 19 13. Dec 19 -519 £10.50 £-5,429
16. Dec 19 Buy Barclays PLC Private Banking & Investment Banking Investment Company 13. Dec 19 13. Dec 19 779 £10.50 £8,169
16. Dec 19 Buy J O Hambro Capital Management Limited Company 13. Dec 19 13. Dec 19 2,300 £10.50 £24,150
13. Dec 19 Sell AXA Investment Managers S.A. Company 12. Dec 19 12. Dec 19 -69,665 £10.48 £-729,741
13. Dec 19 Sell J O Hambro Capital Management Limited Company 12. Dec 19 12. Dec 19 -600 £10.45 £-6,270
13. Dec 19 Sell Barclays PLC Private Banking & Investment Banking Investment Company 12. Dec 19 12. Dec 19 -989 £10.50 £-10,345
13. Dec 19 Buy Barclays PLC Private Banking & Investment Banking Investment Company 12. Dec 19 12. Dec 19 1,433 £10.50 £15,046
12. Dec 19 Buy J O Hambro Capital Management Limited Company 11. Dec 19 11. Dec 19 100 £10.50 £1,050
12. Dec 19 Sell Wellington Management Group LLP Company 11. Dec 19 11. Dec 19 -1,363 £10.45 £-14,243
11. Dec 19 Sell Legal & General Investment Management Limited Company 10. Dec 19 10. Dec 19 -4,414 £10.45 £-46,126
11. Dec 19 Sell BlackRock, Inc. Company 10. Dec 19 10. Dec 19 -41,289 £10.45 £-431,470
11. Dec 19 Sell M&G Investment Management Limited Company 10. Dec 19 10. Dec 19 -2,285 £10.45 £-23,878
11. Dec 19 Buy J O Hambro Capital Management Limited Company 10. Dec 19 10. Dec 19 300 £10.50 £3,150
10. Dec 19 Buy J O Hambro Capital Management Limited Company 09. Dec 19 09. Dec 19 478 £10.48 £5,007
10. Dec 19 Sell Barclays PLC Private Banking & Investment Banking Investment Company 09. Dec 19 09. Dec 19 -541 £10.50 £-5,654
10. Dec 19 Buy Barclays PLC Private Banking & Investment Banking Investment Company 09. Dec 19 09. Dec 19 137 £10.49 £1,435
10. Dec 19 Sell BlackRock, Inc. Company 09. Dec 19 09. Dec 19 -73 £10.46 £-764
09. Dec 19 Buy Aviva Investors Global Services Limited Company 06. Dec 19 06. Dec 19 567 £10.60 £6,010
09. Dec 19 Sell Barclays PLC Private Banking & Investment Banking Investment Company 06. Dec 19 06. Dec 19 -11,201 £10.60 £-118,031
09. Dec 19 Buy Barclays PLC Private Banking & Investment Banking Investment Company 06. Dec 19 06. Dec 19 12,518 £10.60 £131,977
09. Dec 19 Sell Legal & General Investment Management Limited Company 06. Dec 19 06. Dec 19 -5,239 £10.55 £-55,271
09. Dec 19 Buy Legal & General Investment Management Limited Company 06. Dec 19 06. Dec 19 5,239 £10.55 £55,271
06. Dec 19 Buy Janus Henderson Group plc Company 05. Dec 19 05. Dec 19 8,298 £10.43 £86,507
06. Dec 19 Sell Kempen Capital Management N.V. Company 05. Dec 19 05. Dec 19 -306,470 £10.40 £-3,187,288
04. Dec 19 Sell Merian Global Investors (UK) Limited Company 03. Dec 19 03. Dec 19 -383,000 £10.45 £-4,002,350
06. Dec 19 Sell Barclays PLC Private Banking & Investment Banking Investment Company 05. Dec 19 05. Dec 19 -14,876 £10.60 £-157,364
06. Dec 19 Buy Barclays PLC Private Banking & Investment Banking Investment Company 05. Dec 19 05. Dec 19 97,234 £10.60 £1,011,982
06. Dec 19 Sell Wellington Management Group LLP Company 05. Dec 19 05. Dec 19 -24,458 £10.55 £-257,053
05. Dec 19 Sell Kempen Capital Management N.V. Company 04. Dec 19 04. Dec 19 -197,428 £10.40 £-2,053,251
05. Dec 19 Buy Polar Capital Holdings plc Company 04. Dec 19 04. Dec 19 119,077 £10.40 £1,238,401
05. Dec 19 Sell Barclays PLC Private Banking & Investment Banking Investment Company 04. Dec 19 04. Dec 19 -186 £10.45 £-1,944
05. Dec 19 Buy Barclays PLC Private Banking & Investment Banking Investment Company 04. Dec 19 04. Dec 19 60,797 £10.45 £633,447
04. Dec 19 Sell Wellington Management Group LLP Company 03. Dec 19 03. Dec 19 -157,759 £10.45 £-1,641,082
04. Dec 19 Buy BlackRock, Inc. Company 03. Dec 19 03. Dec 19 423 £10.50 £4,441
04. Dec 19 Sell Barclays PLC Private Banking & Investment Banking Investment Company 03. Dec 19 03. Dec 19 -6,865 £10.45 £-71,733
04. Dec 19 Buy Barclays PLC Private Banking & Investment Banking Investment Company 03. Dec 19 03. Dec 19 654,116 £10.46 £6,831,128
04. Dec 19 Sell Kempen Capital Management N.V. Company 03. Dec 19 03. Dec 19 -249,557 £10.40 £-2,595,393
04. Dec 19 Buy Polar Capital Holdings plc Company 03. Dec 19 03. Dec 19 50,000 £10.40 £520,000
04. Dec 19 Sell Schroder Investment Management Limited Company 03. Dec 19 03. Dec 19 -165,000 £10.45 £-1,719,750
02. Dec 19 Sell AXA Investment Managers S.A. Company 29. Nov 19 29. Nov 19 -22,956 £10.45 £-239,890
03. Dec 19 Sell Liontrust Investment Partners LLP Company 02. Dec 19 02. Dec 19 -18,660 £10.50 £-195,930
02. Dec 19 Buy BlackRock, Inc. Company 29. Nov 19 29. Nov 19 1,121 £10.45 £11,714
03. Dec 19 Sell Kempen Capital Management N.V. Company 02. Dec 19 02. Dec 19 -11,586 £10.50 £-121,653
29. Nov 19 Sell Schroder Investment Management Limited Company 28. Nov 19 28. Nov 19 -25,000 £10.50 £-262,500
29. Nov 19 Sell Michael Schumann Individual 18. Nov 19 18. Nov 19 -44,373 £10.40 £-461,479
29. Nov 19 Sell BlackRock, Inc. Company 28. Nov 19 28. Nov 19 -25,120 £10.60 £-266,272
29. Nov 19 Sell Michael Schumann Individual 19. Nov 19 19. Nov 19 -22,495 £10.40 £-233,948
28. Nov 19 Sell Kempen Capital Management N.V. Company 27. Nov 19 27. Nov 19 -7,022 £10.50 £-73,731
28. Nov 19 Sell Invesco Ltd. Company 27. Nov 19 27. Nov 19 -13,865 £10.50 £-145,583
28. Nov 19 Sell J O Hambro Capital Management Limited Company 27. Nov 19 27. Nov 19 -19,165 £10.70 £-205,066
27. Nov 19 Sell Merian Global Investors (UK) Limited Company 26. Nov 19 26. Nov 19 -300,062 £10.50 £-3,150,651
27. Nov 19 Sell Kempen Capital Management N.V. Company 26. Nov 19 26. Nov 19 -21,247 £10.50 £-223,093
25. Nov 19 Sell AXA Investment Managers S.A. Company 22. Nov 19 22. Nov 19 -20,000 £10.50 £-210,000
26. Nov 19 Sell Merian Global Investors (UK) Limited Company 25. Nov 19 25. Nov 19 -8,974 £10.55 £-94,676
25. Nov 19 Sell Merian Global Investors (UK) Limited Company 22. Nov 19 22. Nov 19 -195,964 £10.53 £-2,062,521
25. Nov 19 Buy BlackRock, Inc. Company 22. Nov 19 22. Nov 19 1,401 £10.53 £14,746
22. Nov 19 Sell Dimensional Fund Advisors L.P. Company 21. Nov 19 21. Nov 19 -1,525 £10.50 £-16,013
21. Nov 19 Sell Dimensional Fund Advisors L.P. Company 20. Nov 19 20. Nov 19 -3,023 £10.55 £-31,893
21. Nov 19 Sell Columbia Management Investment Advisers, LLC Company 20. Nov 19 20. Nov 19 -12,428 £10.50 £-130,494
22. Nov 19 Sell Columbia Management Investment Advisers, LLC Company 21. Nov 19 21. Nov 19 -4,103 £10.52 £-43,164
21. Nov 19 Sell Schroder Investment Management Limited Company 20. Nov 19 20. Nov 19 -49,000 £10.55 £-516,950
20. Nov 19 Buy BlackRock, Inc. Company 19. Nov 19 19. Nov 19 705 £10.45 £7,367
19. Nov 19 Sell BlackRock, Inc. Company 18. Nov 19 18. Nov 19 -81,350 £10.40 £-846,040
19. Nov 19 Buy BlackRock, Inc. Company 18. Nov 19 18. Nov 19 2,993 £10.43 £31,173
19. Nov 19 Sell Wellington Management Group LLP Company 18. Nov 19 18. Nov 19 -425,988 £10.43 £-4,430,651
19. Nov 19 Sell Kempen Capital Management N.V. Company 18. Nov 19 18. Nov 19 -105,442 £10.40 £-1,096,597
12. Aug 19 Buy Ian Nicholson Individual 09. Aug 19 09. Aug 19 1,350 £7.36 £9,936
06. Aug 19 Buy Christopher Brinsmead Individual 02. Aug 19 02. Aug 19 1,000 £7.32 £7,319
X
Management checks
We assess Consort Medical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Consort Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CSRTl News

Simply Wall St News

CSRTl Company Info

Description

Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices in Europe, the United States, the United Kingdom, and internationally. It operates through two segments, Bespak and Aesica. The company provides various life improving treatments to patients worldwide through the design, development, and manufacture of medical devices for inhaled, injectable, nasal, and ocular drug delivery, as well as point of care diagnostics products. It also develops, formulates, and manufactures active pharmaceutical ingredients, such as flurbiprofen, and finished dose drugs. Consort Medical plc was incorporated in 1946 and is based in Hemel Hempstead, the United Kingdom.

Details
Name: Consort Medical plc
CSRTl
Exchange: BATS-CHIXE
Founded: 1946
£495,896,193
49,098,633
Website: http://www.consortmedical.com
Address: Consort Medical plc
Breakspear Park,
Suite B,
Hemel Hempstead,
Hertfordshire, HP2 4TZ,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
LSE CSRT Ordinary Shares London Stock Exchange GB GBP 02. Jan 1992
BST 8C7 Ordinary Shares Boerse-Stuttgart DE EUR 02. Jan 1992
BATS-CHIXE CSRTl Ordinary Shares BATS 'Chi-X Europe' GB GBP 02. Jan 1992
Number of employees
Current staff
Staff numbers
2,000
Consort Medical employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/02/17 19:46
End of day share price update: 2020/02/14 00:00
Last estimates confirmation: 2020/02/07
Last earnings filing: 2019/12/03
Last earnings reported: 2019/10/31
Last annual earnings reported: 2019/04/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.